| Literature DB >> 29890656 |
Xian-Qiang Chen1, Li-Gen Lin2, Jing Zhao3,4, Ling-Xiao Chen5, Yu-Ping Tang6, De-Lun Luo7, Shao-Ping Li8.
Abstract
Ganoderma resinaceum has been used as an ethnomedicine for lowering blood sugar. To clarify the bioactive chemical constituents contributing to lower blood sugar, chemical investigation on the fruiting bodies of Ganoderma resinaceum was conducted by chromatographic techniques, and led to the isolation of 14 compounds. Their structures were elucidated as triterpenoid lactones (1⁻4 and 8) and ganoderma acids (5⁻7 and 9⁻14) based on the analysis of extensive spectroscopy (mass spectrometry (MS), nuclear magnetic resonance (NMR), infrared (IR), and ultraviolet (UV)) and comparison with literature data. Compounds 3, 5, 6, and 9⁻14 were evaluated for α-glucosidase inhibitory activity. Compounds 1⁻7 are new compounds. Compounds 1⁻4 and 8 were characteristic of an oxaspirolactone moiety, consisting of a five-membered ether ring, a five-membered lactone ring, and a characteristic C-23 spiro carbon. It is rare for natural products that such an oxaspirolactone moiety occurred in the lanostane-type triterpenoids. Compounds 5⁻7 and 9⁻14 may be important intermediates of the biosynthetic pathways of 1⁻4 and 8. Compounds 1 and 2 showed more potent inhibitory activity against α-glucosidase compared with the positive control drug acarbose with IC50 value of 0.75 ± 0.018 mM and 1.64 ± 0.022 mM, respectively.Entities:
Keywords: Ganoderma resinaceum; oxaspirolactone; triterpenoid; triterpenoid lactone; α-glucosidase inhibitory activity
Mesh:
Substances:
Year: 2018 PMID: 29890656 PMCID: PMC6099967 DOI: 10.3390/molecules23061391
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of compounds 1–14.
1H (600 MHz, CDCl3) and 13C NMR (150 MHz, CDCl3) spectroscopic data for 1–4 and 8 (δ in ppm, J in Hz).
| No | 1 a | 2 | 3 | 4 | 8 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |
|
| 35.21, CH2 | 1.36, dt (13.2, 3.0); | 34.1, CH2 | 1.24, m; 2.83, dt (13.2, 3.0) | 34.7, CH2 | 0.97 dd (13.2, 4.2); | 33.7, CH2 | 1.34, dt (13.8, 3.6); | 34.5, CH2 | 0.92, m; |
|
| 29.0, CH2 | 1.99, m; | 27.5, CH2 | 1.70, dd (12.0, 3.6); | 27.7, CH2 | 1.67, m | 27.3, CH2 | 1.68, dt (12.0, 3.6); | 27.5, CH2 | 1.65, m; |
|
| 77.8, CH | 3.52, dd overlapped | 77.3, CH | 3.29, dd (11.4, 4.8) | 78.2, CH | 3.22, dd (11.4, 4.8) | 77.5, CH | 3.30, dd (11.4, 4.2) | 78.2, CH | 3.23, dd (11.4, 4.8) |
|
| 39.7, C | 38.7, C | 38.9, C | 39.0, C | 38.6, C | |||||
|
| 52.4, CH | 1.18, br d (12.0) | 49.3, CH | 1.55, dd (9.6, 7.8) | 49.0, CH | 0.88, br d (12.0) | 49.9, CH | 1.63, dd overlapped | 48.9, CH | 0.92, d (12.0) |
|
| 17.9, CH2 | 1.51, m; 1.84, m | 36.2, CH2 | 2.56, m; 2.57, m | 26.6, CH2 | 1.59, dt (13.2, 3.6); 2.19, dd (13.2, 8.4) | 35.9, CH2 | 2.58, m; 2.62, m | 27.7, CH2 | 1.61, m; 1.65, m |
|
| 30.7, CH2 | 2.76, dd (21.0, 5.4); | 205.0, C | 66.7, CH | 4.81, m | 198.5, C | 69.0, CH | 4.60, br t (6.6) | ||
|
| 165.2, C | 150.3, C | 157.5, C | 148.9, C | 158.7, C | |||||
|
| 139.9, C | 154.5, C | 142.4, C | 151.5, C | 141.6, C | |||||
|
| 38.4, C | 40.0, C | 38.6, C | 40.4, C | 38.5, C | |||||
|
| 198.6, C | 201.8, C | 198.1, C | 200.2, C | 200.2, C | |||||
|
| 47.4, CH2 | 2.46, d (16.8); | 47.2, CH2 | 2.35, d (16.8); | 44.1, CH2 | 2.48, d (16.8); | 44.7, CH2 | 2.48, d (16.2); | 47.0, CH2 | 2.27, d (15.0); |
|
| 50.2, C | 50.7 C | 48.1, C | 47.3, C | 49.5, C | |||||
|
| 54.4, C | 53.5, C | 59.1, C | 56.5, C | 54.3, C | |||||
|
| 72.9, CH | 4.72, dd (9.0, 7.2) | 72.7, CH | 4.45, dd (9.0, 7.2) | 216.1, C | 207.1, C | 73.0, CH | 4.80, t (8.4) | ||
|
| 47.3, CH2 | 2.52, dd (15.0, 9.0); | 44.3, CH2 | 2.32, dd (15.6, 9.0); | 48.0, CH2 | 2.47, d (20.4); | 48.1, CH2 | 2.45, d (16.2); | 44.7, CH2 | 2.29, m; |
|
| 95.6, C | 94.7, C | 91.8, C | 92.2, C | 94.7, C | |||||
|
| 19.8, CH3 | 1.15, s | 20.0, CH3 | 1.05, s | 20.9, CH3 | 1.18, s | 20.0, CH3 | 1.03, s | 19.7, CH3 | 1.16, s |
|
| 19.4, CH3 | 1.42, s | 17.4, CH3 | 1.29, s | 18.3, CH3 | 1.21, s | 17.7, CH3 | 1.20, s | 19.4, CH3 | 1.26, s |
|
| 43.7, CH | 2.14, m | 43.6, CH | 2.26, m | 43.1, CH | 2.38, m | 43.3, CH | 2.38, m | 48.3, CH | 2.29, m |
|
| 17.9, CH3 | 0.91, d (6.6) | 18.1, CH3 | 1.01, d (6.6) | 18.2, CH3 | 1.12, d (6.6) | 18.3, CH3 | 1.10, d (7.2) | 18.1, CH3 | 1.02, d (7.2) |
|
| 44.61, CH2 | 1.76 d (13.8); | 44.6, CH2 | 1.81, d (13.8); | 44.4, CH2 | 1.93, d (14.4); | 44.3, CH2 | 1.91, d (14.4); | 44.6, CH2 | 1.84, d (14.4); |
|
| 113.3, C | 112.7, C | 113.0, C | 112.9, C | 113.3, C | |||||
|
| 44.62, CH2 | 1.96, d (12.6); | 44.9, CH2 | 2.03, dd (12.6, 11.4); | 44.5, CH2 | 2.10, dd (13.2, 11.4); | 44.6, CH2 | 2.09, dd (12.6, 11.4); | 44.7, CH2 | 2.05, dd (12.6, 11.4); |
|
| 35.7, CH | 3.02, m | 35.4, CH | 2.92, m | 35.4, CH | 2.92, m | 35.3, CH | 2.94, m | 35.5, CH | 2.96, m |
|
| 178.7, C | 178.5, C | 178.3, C | 178.2, C | 179.2, C | |||||
|
| 15.1, CH3 | 1.23, d (7.2) | 14.9, CH3 | 1.25, d (6.6) | 14.9, CH3 | 1.29, d (7.2) | 14.9, CH3 | 1.28, d (7.2) | 14.9, CH3 | 1.28, d (7.2) |
|
| 28.9, CH3 | 1.27, s | 27.7, CH3 | 1.03, s | 28.2, CH3 | 1.04, s | 27.7, CH3 | 1.03, s | 28.1, CH3 | 1.03, s |
|
| 16.8, CH3 | 1.13, s | 15.4, CH3 | 0.89, s | 15.5, CH3 | 0.87, s | 15.4, CH3 | 0.89, s | 15.7, CH3 | 0.85, s |
|
| 21.8, CH3 | 1.68, s | 22.6, CH3 | 1.24, s | 26.9, CH3 | 1.41, s | 25.8, CH3 | 1.54, s | 21.2, CH3 | 1.33, s |
a Recorded in pyridine-d5.
Figure 2The key COSY, HMBC, and ROESY correlations of 1–7. Bold line (–): hydrogen-hydrogen correlation in the correlation spectroscopy (COSY) spectrum. One-way arrows (→): heteronuclear multiple bond correlation from hydrogen to carbon in the heteronuclear multiple bond correlation (HMBC) spectrum. Double sided arrows (↔): the correlations between hydrogen and hydrogen in the rotating-frame nuclear overhauser effect correlation spectroscopy (ROESY) spectrum.
1H (600 MHz, CD3OD) and 13C (150 MHz, CD3OD) NMR spectroscopic data for 5–7 (δ in ppm, J in Hz).
| No | 5 | 6 | 7 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 35.2, CH2 | 1.37, dd (13.2, 4.2); | 35.4, CH2 | 1.29, m; 2.92, dt (13.8, 3.6) | 35.8, CH2 | 1.08, dd (13.2, 3.6); |
|
| 28.1, CH2 | 1.62, m | 28.6, CH2 | 1.69, m; 1.74, m | 28.6, CH2 | 1.62, m; 1.68, m |
|
| 78.4, CH | 3.18, dd (11.4, 4.8) | 78.2, CH | 3.22, dd (11.4, 4.8) | 79.5, CH | 3.17, dd (11.4, 4.8) |
|
| 40.1, C | 40.1, C | 40.3, C | |||
|
| 50.5, CH | 1.71, dd (13.8, 4.2) | 51.5, CH | 1.58, dd (15.0, 1.8) | 53.7, CH | 0.95, d (13.2) |
|
| 36.0, CH2 | 2.49, d (13.8); | 36.8, CH2 | 2.55, m; 2.70, t (15.0) | 18.7, CH2 | 1.51, m; 1.81, m |
|
| 200.3, C | 206.3, C | 32.9, CH2 | 2.55, m | ||
|
| 151.5, C | 150.9, C | 166.5, C | |||
|
| 154.0, C | 155.94, C | 140.9, C | |||
|
| 42.0, C | 41.8, C | 39.4, C | |||
|
| 200.8, C | 202.6, C | 201.2, C | |||
|
| 45.6, CH2 | 2.54, d (16.8); | 48.9, CH2 | 2.42, d (16.2); | 48.7, CH2 | 2.24, d (16.8); |
|
| 53.2, C | 53.8, C | 53.4, C | |||
|
| 56.6, C | 55.3, C | 58.0, C | |||
|
| 206.7, C | 78.4, CH | 4.95, br s | 77.8, CH | 4.90, br s | |
|
| 124.0, CH | 5.65, s | 124.5, CH | 5.26, s | 125.7, CH | 5.18, s |
|
| 186.7, C | 155.98, C | 156.3, C | |||
|
| 30.1, CH3 | 1.02, s | 23.3, CH3 | 0.95, s | 23.0, CH3 | 0.96, s |
|
| 17.7, CH3 | 1.08, s | 17.7, CH3 | 1.30, s | 19.4, CH3 | 1.12, s |
|
| 30.7, CH | 2.93, m | 28.5, CH | 2.63, m | 28.9, CH | 2.62, m |
|
| 20.1, CH3 | 1.05, d (6.6) | 21.0, CH3 | 1.04, d (6.6) | 21.0, CH3 | 1.04, d (7.2) |
|
| 48.5, CH2 | 2.70, dd (17.4, 5.4); | 49.4, CH2 | 2.57, d (16.8); | 49.5, CH2 | 2.54, d (16.8); |
|
| 209.0, C | 209.9, C | 210.0, C | |||
|
| 47.3, CH2 | 2.49, m; | 47.5, CH2 | 2.53, m; | 47.5, CH2 | 2.52, dd (13.2, 8.4); |
|
| 36.2, CH | 2.78, m | 36.0, CH | 2.82, m | 36.1, CH | 2.83, m |
|
| 179.6, C | 179.9, C | 179.8, C | |||
|
| 17.7, CH3 | 1.09, d (7.2) | 17.7, CH3 | 1.14, d (7.2) | 17.7, CH3 | 1.15, d (6.6) |
|
| 28.3, CH3 | 0.96, s | 28.3, CH3 | 1.00, s | 29.1, CH3 | 1.02, s |
|
| 16.0, CH3 | 0.83, s | 16.2, CH3 | 0.89, s | 16.6, CH3 | 0.82, s |
|
| 33.6, CH3 | 1.39, s | 23.2, CH3 | 1.17, s | 22.7, CH3 | 1.21, s |
Figure 3Plausible biogenetic pathway for 1–4 and 8. A, B, and C are supposed intermediates in the biosynthetic pathway of compounds 1–4 and 8. Intermediate A included compounds 11–14. Intermediate B included compounds 5–7, 9, and 10. At present, the representative compounds of intermediate C are not obtained from Ganoderma resinaceum.